Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Immix Biopharma, Inc. - Common Stock
(NQ:
IMMX
)
2.030
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immix Biopharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial
June 26, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors
June 22, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors
June 20, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors
June 16, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program
June 14, 2023
Participating institutional investors include Bridgewest Group
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors
June 12, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site
May 26, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 26, 2023
Via
Benzinga
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
May 22, 2023
Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share.
Via
Benzinga
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
May 22, 2023
Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 22, 2023
Via
Benzinga
Why Immix Biopharma Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
May 22, 2023
Gainers SeqLL Inc. (NASDAQ: SQL) shares surged 61.1% to $0.54 in pre-market trading after dropping 14% on Friday. SeqLL recently posted a wider first-quarter loss.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
May 22, 2023
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday!
Via
InvestorPlace
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
May 04, 2023
•Updated clinical data for next-generation CAR-T NXC-201 in AL amyloidosis will be presented in Los Angeles May 16-20, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
What's Going On With Immix Biopharma Stock Today
May 03, 2023
Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG'
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 03, 2023
Via
Benzinga
Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab
May 03, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
April 27, 2023
Via
Benzinga
Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 27, 2023
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its...
Via
Benzinga
Why Meta Platforms Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
April 27, 2023
Gainers
Via
Benzinga
Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
April 26, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting
April 04, 2023
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Paris, France 23-26 April 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
March 31, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Nexcella, an Immix Biopharma Subsidiary, Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment
March 23, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank
March 10, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14
March 06, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 23, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 22, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
February 22, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 22, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.